Plain-English translation of NCT06593964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study compares two different materials used during a procedure called TACE (a minimally invasive treatment where doctors inject medicine and blocking material directly into the blood vessels feeding liver cancer). Half of participants will receive treatment with a thermosensitive nanogel embolic agent, while the other half will receive the standard embosphere microspheres. The goal is to see if the new gel material is just as safe and effective as the traditional microspheres.
For patients with liver cancer that cannot be removed by surgery, TACE is an important treatment option. Researchers want to know whether this newer gel-based material might work better, cause fewer side effects, or improve outcomes compared to the microspheres currently used.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive TACE with either the new thermosensitive nanogel or the standard embosphere microspheres. The procedure itself involves a catheter (thin tube) placed into the blood vessel supplying your tumor, through which the medicine and blocking material are injected. The main check-in will be at 1 month after your last treatment, when doctors will use imaging scans to see how well the tumor responded. Your participation helps doctors understand whether the new material might be a better option for future patients.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Sponsor
Zhongda Hospital
Enrollment target
~188 participants
Started
September 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lei Zhang, M.D.
Zhongda Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.